Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213074975> ?p ?o ?g. }
- W4213074975 abstract "Despite the remarkable breakthroughs achieved in the management of metastatic melanoma using immunotherapy and targeted therapies, long-term clinical efficacy is often compromised due to dose-limiting toxicity and innate or acquired resistance. Therefore, it is of vital importance to further explore the molecular mechanisms underlying melanoma progression and identify new targeted therapeutic approaches.The function of eukaryotic elongation factor-2 kinase (EEF2K) in melanoma were investigated in vitro and in vivo. RNA-seq and chromatin immunoprecipitation (ChIP) assay were undertaken to explore the mechanisms. The antitumor effect of bromodomain and extra terminal domain (BET) inhibitors combined with cytarabine were assessed in melanoma both in vitro and in vivo.EEF2K silencing markedly attenuated the malignant phenotypes of melanoma cells, including proliferation, migration, invasion and metastasis. In contrast, EEF2K overexpression promoted melanoma cell proliferation, migration and invasion. Mechanistically, we demonstrated that EEF2K upregulates the phosphorylation of STAT3 (p-STAT3) at Tyr705, which binds to the promoter region of SPP1 and enhances its transcription, thus facilitating melanoma progression. Transfection-induced re-expression of SPP1 partly negated the inhibitory effect of EEF2K silencing on melanoma, whereas inhibition of SPP1 or STAT3 significantly abolished the efficacy of EEF2K on melanoma cells. Intriguingly, EEF2K silencing combined with BET inhibitor treatment further inhibited cell proliferation and promoted apoptosis in melanoma. We further screened the US FDA-approved antitumour drug library and identified cytarabine as a potential clinically applicable EEF2K inhibitor that could synergise with BET inhibitors in melanoma treatment.EEF2K/p-STAT3/SPP1 may be a novel oncogenic pathway in melanoma progression, which could be a target for novel combination therapy for melanoma." @default.
- W4213074975 created "2022-02-24" @default.
- W4213074975 creator A5006718110 @default.
- W4213074975 creator A5015347248 @default.
- W4213074975 creator A5021389154 @default.
- W4213074975 creator A5022806069 @default.
- W4213074975 creator A5031061480 @default.
- W4213074975 creator A5034673563 @default.
- W4213074975 creator A5034678534 @default.
- W4213074975 creator A5036994170 @default.
- W4213074975 creator A5076768386 @default.
- W4213074975 creator A5083022010 @default.
- W4213074975 date "2022-02-01" @default.
- W4213074975 modified "2023-10-17" @default.
- W4213074975 title "EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma" @default.
- W4213074975 cites W1966766450 @default.
- W4213074975 cites W1970579022 @default.
- W4213074975 cites W1971405891 @default.
- W4213074975 cites W2000707284 @default.
- W4213074975 cites W2012265269 @default.
- W4213074975 cites W2015136946 @default.
- W4213074975 cites W2027552663 @default.
- W4213074975 cites W2043064250 @default.
- W4213074975 cites W2046634347 @default.
- W4213074975 cites W2054982539 @default.
- W4213074975 cites W2059287377 @default.
- W4213074975 cites W2061230387 @default.
- W4213074975 cites W2064597980 @default.
- W4213074975 cites W2075064678 @default.
- W4213074975 cites W2075441508 @default.
- W4213074975 cites W2077945404 @default.
- W4213074975 cites W2081479137 @default.
- W4213074975 cites W2106404376 @default.
- W4213074975 cites W2131382859 @default.
- W4213074975 cites W2134913638 @default.
- W4213074975 cites W2146936606 @default.
- W4213074975 cites W2365741387 @default.
- W4213074975 cites W2507956776 @default.
- W4213074975 cites W2559878102 @default.
- W4213074975 cites W2605233023 @default.
- W4213074975 cites W2770145603 @default.
- W4213074975 cites W2799625219 @default.
- W4213074975 cites W2801012801 @default.
- W4213074975 cites W2811008574 @default.
- W4213074975 cites W2918091924 @default.
- W4213074975 cites W2962428370 @default.
- W4213074975 cites W2976373838 @default.
- W4213074975 cites W2992707470 @default.
- W4213074975 cites W3010899941 @default.
- W4213074975 cites W3015646212 @default.
- W4213074975 cites W3023135453 @default.
- W4213074975 cites W3088093311 @default.
- W4213074975 cites W3110058912 @default.
- W4213074975 cites W3117478370 @default.
- W4213074975 cites W3119005666 @default.
- W4213074975 cites W3126480466 @default.
- W4213074975 cites W3132280781 @default.
- W4213074975 cites W3134791058 @default.
- W4213074975 cites W3155992794 @default.
- W4213074975 doi "https://doi.org/10.1002/ctm2.722" @default.
- W4213074975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35184394" @default.
- W4213074975 hasPublicationYear "2022" @default.
- W4213074975 type Work @default.
- W4213074975 citedByCount "6" @default.
- W4213074975 countsByYear W42130749752022 @default.
- W4213074975 countsByYear W42130749752023 @default.
- W4213074975 crossrefType "journal-article" @default.
- W4213074975 hasAuthorship W4213074975A5006718110 @default.
- W4213074975 hasAuthorship W4213074975A5015347248 @default.
- W4213074975 hasAuthorship W4213074975A5021389154 @default.
- W4213074975 hasAuthorship W4213074975A5022806069 @default.
- W4213074975 hasAuthorship W4213074975A5031061480 @default.
- W4213074975 hasAuthorship W4213074975A5034673563 @default.
- W4213074975 hasAuthorship W4213074975A5034678534 @default.
- W4213074975 hasAuthorship W4213074975A5036994170 @default.
- W4213074975 hasAuthorship W4213074975A5076768386 @default.
- W4213074975 hasAuthorship W4213074975A5083022010 @default.
- W4213074975 hasBestOaLocation W42130749753 @default.
- W4213074975 hasConcept C101762097 @default.
- W4213074975 hasConcept C104317684 @default.
- W4213074975 hasConcept C119056186 @default.
- W4213074975 hasConcept C134320426 @default.
- W4213074975 hasConcept C150194340 @default.
- W4213074975 hasConcept C22615655 @default.
- W4213074975 hasConcept C2777658100 @default.
- W4213074975 hasConcept C2778923194 @default.
- W4213074975 hasConcept C502942594 @default.
- W4213074975 hasConcept C54009773 @default.
- W4213074975 hasConcept C54355233 @default.
- W4213074975 hasConcept C55493867 @default.
- W4213074975 hasConcept C62478195 @default.
- W4213074975 hasConcept C71924100 @default.
- W4213074975 hasConcept C81885089 @default.
- W4213074975 hasConcept C86803240 @default.
- W4213074975 hasConcept C95444343 @default.
- W4213074975 hasConceptScore W4213074975C101762097 @default.
- W4213074975 hasConceptScore W4213074975C104317684 @default.
- W4213074975 hasConceptScore W4213074975C119056186 @default.
- W4213074975 hasConceptScore W4213074975C134320426 @default.
- W4213074975 hasConceptScore W4213074975C150194340 @default.